Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

3.980 +0.050 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,607,767
Open 3.950
Bid (Size) 3.980 (2)
Ask (Size) 4.060 (29)
Prev. Close 3.930
Today's Range 3.880 - 4.025
52wk Range 0.4902 - 5.125
Shares Outstanding 103,119,010
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire

Performance

YTD
+48.51%
+48.51%
1 Month
-8.72%
-8.72%
3 Month
+11.80%
+11.80%
6 Month
+123.60%
+123.60%
1 Year
+494.03%
+494.03%

More News

Read More
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Recap: Ardelyx Q1 Earnings
Via Benzinga
Earnings Preview For Ardelyx
Via Benzinga
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/18
Via Investor Brand Network
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/13
Via Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/5
Via Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/3
Via Investor Brand Network
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
7 High-Potential Penny Stocks in the Biotech Sector
Via InvestorPlace
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 3/30
Via Investor Brand Network
Ardelyx Earnings Perspective: Return On Capital Employed
Via Benzinga
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
3 Penny Stocks to Add to Your Watchlist for Potential Breakouts
Via InvestorPlace
7 A-Rated Stocks to Buy for April 2023
Via InvestorPlace
7 Core Stocks to Build a Solid Portfolio Around
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.